Cancer risk in systemic lupus: An updated international multi-centre cohort study

Journal of Autoimmunity

Volumn 42, Issue , 2013, Pages 130-135

  Bernatsky, Sasha ^a,c   Ramsey Goldman, Rosalind ^b   Labrecque, Jeremy ^a   Joseph, Lawrence ^a,c   Boivin, Jean Francois ^c   Petri, Michelle ^d   Zoma, Asad ^e   Manzi, Susan ^f   Urowitz, Murray B ^g   Gladman, Dafna ^g   Fortin, Paul R ^h   Ginzler, Ellen ⁱ   Yelin, Edward ^j   Bae, Sang Cheol ^k   Wallace, Daniel J ^l   Edworthy, Steven ^m   Jacobsen, Soren ⁿ   Gordon, Caroline ^o   Dooley, Mary Anne ^p   Peschken, Christine A ^q   Hanly, John G ^r   Alarcón, Graciela S ^s   Nived, Ola ^t   Ruiz Irastorza, Guillermo ^u   Isenberg, David ^v   Rahman, Anisur ^v   Witte, Torsten ^w   Aranow, Cynthia ^x   Kamen, Diane L ^y   Steinsson, Kristjan ^z   Askanase, Anca ^aa   Barr, Susan ^m   Criswell, Lindsey A ^j   Sturfelt, Gunnar ^t   Patel, Neha M ⁱ   Senécal, Jean Luc ^ab   Zummer, Michel ^ab   Pope, Janet E ^ac   Ensworth, Stephanie ^ad   El Gabalawy, Hani ^q   McCarthy, Timothy ^q   Dreyer, Lene ⁿ   Sibley, John ^ae   St Pierre, Yvan ^a   Clarke, Ann E ^a   more..

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HAIRMYRES HOSPITAL   (United Kingdom)

^f ALLEGHENY GENERAL HOSPITAL   (United States)

^g TORONTO WESTERN HOSPITAL   (Canada)

^h UNIVERSITÉ LAVAL   (Canada)

ⁱ SUNY DOWNSTATE MEDICAL CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF CALGARY   (Canada)

ⁿ Rigshospitalet   (Denmark)

^o UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^p UNIVERSITY OF NORTH CAROLINA   (United States)

^q UNIVERSITY OF MANITOBA   (Canada)

^r DALHOUSIE UNIVERSITY   (Canada)

^s UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^t LUND UNIVERSITY HOSPITAL   (Sweden)

^u HOSPITAL DE CRUCES   (Spain)

^v UNIVERSITY COLLEGE LONDON   (United Kingdom)

^w HANNOVER MEDICAL SCHOOL   (Germany)

^x FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^y MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^z LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^aa NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ab UNIVERSITÉ DE MONTRÉAL   (Canada)

^ac UNIVERSITY OF WESTERN ONTARIO   (Canada)

^ad UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^ae ROYAL UNIVERSITY HOSPITAL   (Canada)

more..

Author keywords

Disease activity; Epidemiology; Systemic lupus erythematosus; Treatment

Indexed keywords

ADULT; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; ENDOMETRIUM CANCER; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MULTIPLE MYELOMA; NEOPLASM; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; STOMACH CANCER; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID CANCER; UTERINE CERVIX CANCER; VAGINA CANCER; VULVA CANCER;

ADULT; ASIA; BREAST NEOPLASMS; CANADA; COHORT STUDIES; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTERNATIONAL COOPERATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASMS; OVARIAN NEOPLASMS; RISK; UNITED STATES;

EID: 84877148183     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.12.009     Document Type: Article

References (35)

1. Zintzaras E., Voulgarelis M., Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005, 165(20):2337-2344.
2. Kassan S.S., Thomas T.L., Moutsopoulos H.M., Hoover R., Kimberly R.P., Budman D.R., et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978, 89(6):888-892.
3. Bernatsky S., Boivin J., Joseph L., St Pierre Y., Moore A., Rajan R., et al. The prevalence of factors influencing cancer risk in lupus: social habits reproductive issues and obesity. J Rheumatol 2002, 29(12):2551-2554.
4. Lofstrom B., Backlin C., Pettersson T., Lundberg I.E., Baecklund E. Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 2011, 38(9):1891-1897.
5. Abu-Shakra M., Gladman D.D., Urowitz M.B. Malignancy in systemic lupus erythematosus. Arthritis Rheum 1996, 39(6):1050-1054.
6. Pettersson T., Pukkala E., Teppo L., Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992, 51(4):437-439.
7. Bernatsky S., Boivin J., Lawrence J., Rajan R., Zoma A., Manzi S., et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005, 52(5):1481-1490.
8. Smitten A.L., Simon T.A., Hochberg M.C., Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008, 10(2):R45.
9. Ott G., Rosenwald A. Molecular pathogenesis of follicular lymphoma. Haematologica 2008, 93(12):1773-1776.
10. Voulgarelis M., Skopouli F.N. Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients. Clin Rev Allergy Immunol 2007, 32(3):265-274.
11. Dias C., Isenberg D.A. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol 2011, 7(6):360-368.
12. Bernatsky S., Ramsey-Goldman R., Rajan R., Boivin J.F., Joseph L., Lachance S., et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005, 64(10):1507-1509.
13. Bernatsky S., Ramsey-Goldman R., Gordon C., Manzi S., Nived O., Bae S.C., et al. Histology, prognostic factors, treatment, and outcome in SLE patients with non-Hodgkins lymphoma [Abstract]. Arthritis Rheum 2009, 60(Suppl.):S1933.
14. Bernatsky S., Boivin J.F., Joseph L., Gordon C., Urowitz M., Gladman D., et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann Rheum Dis 2008, 67:74-79.
15. Bin J., Bernatsky S., Gordon C., Boivin J.F., Ginzler E., Gladman D., et al. Lung cancer in systemic lupus erythematosus. Lung Cancer 2007, 56(3):303-306.
16. Mok C.C., Ho L.Y., Fong L.S., To C.H. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2012 May 15, [Epub ahead of print].
17. Chao C., Klein N.P., Velicer C.M., Sy L.S., Slezak J.M., Takhar H., et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012, 271(2):193-203.
18. Antonelli A., Fallahi P., Mosca M., Ferrari S.M., Ruffilli I., Corti A., et al. Prevalence of thyroid dysfunctions in systemic lupus erythematosus. Metabolism 2010, 59(6):896-900.
19. Azizi G., Malchoff C.D. Autoimmune thyroid disease: a risk factor for thyroid cancer. Endocr Pract 2011, 17(2):201-209.
20. Antonelli A., Mosca M., Fallahi P., Neri R., Ferrari S.M., D'Ascanio A., et al. Thyroid cancer in systemic lupus erythematosus: a case-control study. J Clin Endocrinol Metab 2010, 95(1):314-318.
21. Bernatsky S., Ramsey-Goldman R., Foulkes W., Gordon C., Clarke A. Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer 2011, 104:1478-1481.
22. Bernatsky S., Clarke A., Petri M.A., Urowitz M., Fortin P., Gladman D., et al. Further defining cancer risk in systemic lupus: updated results in an expanded international multi-centre cohort. Arthritis Rheum 2010, 62(Suppl.):S731.
23. Moran E.M. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 2002, 21(2):193-201.
24. Akhmedkhanov A., Toniolo P., Zeleniuch-Jacquotte A., Koenig K.L., Shore R.E. Aspirin and lung cancer in women. Br J Cancer 2002, 87(1):49-53.
25. Boivin J.F., Hutchison G.B., Zauber A.G., Bernstein L., Davis F.G., Michel R.P., et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 1995, 87(10):732-741.
26. Ruiz-Irastorza G., Ugarte A., Egurbide M.V., Garmendia M., Pijoan J.I., Martinez-Berriotxoa A., et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 2007, 66(6):815-817.
27. Rahim R., Strobl J.S. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 2009, 20(8):736-745.
28. Amaravadi R.K. Autophagy-induced tumor dormancy in ovarian cancer. J Clin Invest 2008, 118(12):3837-3840.
29. Bernatsky S., Ramsey-Goldman R., Gordon C., Foulkes W., Clarke A. Decreased breast cancer risk in SLE: can a genetic basis be determined?. Arthritis Rheum 2011, 62(Suppl.):S19089.
30. Bernatsky S., Clarke A., Ramsey-Goldman R., Boivin J.F., Joseph L., Rajan R., et al. Breast cancer stage at time of detection in women with systemic lupus erythematosus. Lupus 2004, 13(6):469-472.
31. Bernatsky S.R., Cooper G.S., Mill C., Ramsey-Goldman R., Clarke A.E., Pineau C.A. Cancer screening in patients with systemic lupus erythematosus. J Rheumatol 2006, 33(1):45-49.
32. Bernatsky S., Boivin J., Manzi S., Ginzler E., Gladman D.D., Urowitz M.B., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54(8):2550-2557.
33. Bernatsky S., Boivin J.F., Joseph L., Manzi S., Ginzler E., Urowitz M., et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum 2005, 53(5):781-784.
34. Mayo Clinic Heart Disease Calculator. [accessed Nov. 2012]. http://www.mayoclinic.com/health/heart-disease-risk/HB00047.
35. Na H.K., Oliynyk S. Effects of physical activity on cancer prevention. Ann N Y Acad Sci 2011, 1229(1):176-183.